← Research library

Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease

Controlled study in people · 2000

What was studied
Three groups: two Semax administration routes and a control; sample size not established here
Main finding
A three-group optic-nerve report described faster visual recovery when Semax was added to neurotrophic and anti-inflammatory care, without numerical visual-acuity or field changes in its abstract.

Reported findings and study design

A three-group optic-nerve report described faster visual recovery when Semax was added to neurotrophic and anti-inflammatory care, without numerical visual-acuity or field changes in its abstract.

Vascular, toxic-allergic, inflammatory and partial-atrophy optic-nerve conditions; intranasal, endonasal-electrophoresis and control groups.

Population or model Three groups: two Semax administration routes and a control; sample size not established here

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Visual outcomesReported improvement in acuity, total visual field, color vision and optic-nerve electrical measuresNo effect size or arm counts supplied
Treatment comparison2 Semax delivery groups and 1 control groupAll within a therapeutic package

Route and combination-care effects cannot be separated from the abstract. This does not quantify visual benefit in a specific modern diagnosis.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • Background treatment complicates attribution.
  • Allocation, blinding and numerical treatment effects require full-text review.

Source details

Journal publication

Indexed citation and English abstract checked; full methods and risk of bias not appraised.

Sources checked

Citation

Clinical trial / comparisonEnglish abstract

G S Polunin, S M Nurieva, D L Baiandin, N L Sheremet, L A Andreeva. Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease Vestn Oftalmol. 116(1):15–18

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards